A Study to Learn More About How Well the Study Treatment Finerenone Works
Phase 3
219
about 5.4 years
0.5–17
19 sites in AZ, CA, DC +12
What this study is about
This trial is testing whether finerenone, taken with an ACE inhibitor or angiotensin receptor blocker, helps reduce protein in urine for children with chronic kidney disease. Researchers will also examine how well finerenone works and its safety profile.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Finerenone (Kerendia, BAY94-8862)
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
finerenone
oral (Oral Tablet)
Primary: Percent change in Urinary protein-to-creatinine ratio (UPCR) reduction from baseline to day 180+/-7
Secondary: Change in eGFR from baseline to day 180±7, Change in serum creatinine from baseline to day 180±7, Change in systolic blood pressure from baseline to day 180±7, Number participants with treatment emergent adverse events (TEAEs）, Pharmacokinetics (PK) finerenone AUCτ,md, Pharmacokinetics (PK) finerenone Cmax, md
Renal